Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma

Foote, Matthew; McGrath, Margaret; Guminski, Alexander; Hughes, Brett; Meakin, J. W.; Thomson, Damien; Zarate, Dannie; Simpson, Fiona; Porceddu, Sandro

doi:10.1093/annonc/mdu368

Cited by 137 publications

(90 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5] Prospective phase II studies have been conducted but enrolled under 50 patients. 8 In both of these studies, almost all patients had unresectable, locoregionally advanced disease. 6 The use of epidermal growth factor receptor inhibitors, cetuximab, panitumumab, and gefitinib, have been studied with cetuximab demonstrating an 27% overall response rate and a median survival of 8.1 months in 36 patients.…”

Section: Introductionmentioning

confidence: 95%

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 95%

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Efficacy of the EGFR blockade has been observed for BCC and SCC: Gefitinib, a small molecule that inhibits EGFR, and panitumumab, a completely humanized monoclonal antibody directed against EGFR, have been demonstrated to have a certain amount of activity in NMSC (47,48). This last feature may depend on the biology of NMSC, since the EGFR pathway is often deregulated in SCC and in BCC.…”

Section: Resultsmentioning

confidence: 99%

Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas

Scarpati

Perri

Pisconti

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Non-melanoma skin cancers (NMSCs) include a heterogeneous group of malignancies arising from the epidermis, comprising squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Merkel cell carcinoma and more rare entities, including malignant pilomatrixoma and sebaceous gland tumours. The treatment of early disease depends primarily on surgery. In addition, certain patients present with extensive local invasion or metastasis, which renders these tumours surgically unresectable. Improving the outcome of radiotherapy through the use of concurrent systemic therapy has been demonstrated in several locally advanced cancer-treatment paradigms. Recently, agents targeting the human epidermal growth factor receptor (EGFR) have exhibited a consolidated activity in phase II clinical trials and case series reports. Cetuximab is a monoclonal antibody that binds to and completely inhibits the EGFR, which has been revealed to be up-regulated in a variety of SCCs, including NMSCs. The present review aimed to summarize the role of anti-EGFR agents in the predominant types of NMSC, including SCC and BCC, and focuses on the cetuximab-based studies, highlighting the biological rationale of this therapeutic option. In addition, the importance of the association between cetuximab and radiotherapy for locally advanced NMSC is discussed.

show abstract

“…89 The promising human immunoglobulin G-2 monoclonal antibody against EGFR, panitumumab, demonstrated a 31% response rate in a phase II study of 16 patients with recurrent or metastatic SCC. 90 In a larger phase III with 51 patients, however, only a 4% response was recorded. To date, only cetuximab has been granted FDA approval.…”

Section: Novel Treatmentsmentioning

confidence: 97%

High-risk Cutaneous Squamous Cell Carcinoma

Fitzgerald¹,

O’Neill²

2017

International Journal of Head and Neck Surgery

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer worldwide. Cutaneous squamous cell carcinoma can potentially be treated fully with minimal morbidity when detected early; however, certain subtypes of cSCC have been shown to confer a poorer prognosis for patients. In these high-risk tumors, increased incidence of recurrence, as well as metastasis to local lymph nodes and distant sites, is seen as a result of certain patient characteristics and pathological features. While guidelines regarding the management of high-risk cSCC have been produced, no clear consensus management or prognostic algorithms exist. In this review, we discuss current definitions of high-risk cSCC, recommendations regarding the management of cSCC, and current guidelines.

show abstract

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma

Abstract: Single-agent panitumumab is safe and effective in the management of patients with advanced CSCC even in a previously extensively pre-treated cohort.

Cited by 137 publications

References 19 publications

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas

High-risk Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About